علاج الحزاز البسيط المزمن في المناطق الحساسة تشريحياً عند عدم تحمل العوامل الموضعية

References

DOI: 10.1007/s40257-025-00979-z

• In anatomically sensitive areas such as the genital region, where topical agents may be poorly tolerated, systemic treatments may be required.
• A case series of three women with vulvar LSC refractory to steroids and immunomodulators found dupilumab led to marked relief of vulvar pruritus and thinning of lichenified skin, with lesions worsening again after drug discontinuation.
• This supports the consideration of systemic biologic therapy in anatomically sensitive or treatment-refractory cases of LSC, where topical agents are poorly tolerated or insufficient for disease control, particularly in areas such as the genital region where symptom burden is high and steroid use may be limited.
• Dupilumab is undergoing phase 3 trials for LSC of the skin and genitals.
• Nemolizumab, an IL-31 receptor antibody may show promise in relieving the itch-scratch cycle in LSC, as it has a significant antipruritic effect on multiple itchy conditions beyond its effect in atopic eczema and PN.